Clomid Compounded Equivalent: What You Can Actually Get, What It Costs, and What to Watch Out For

The Short Answer on Compounded Clomiphene

Compounded drugs fill a gap when a brand-name or generic is unavailable, prohibitively expensive, or needs to be formulated differently (a liquid for someone who can't swallow tablets, for example). For clomiphene citrate, that gap is narrow. Generic clomiphene has been off patent for decades, and the cash price at most major pharmacies sits around $30 for a full cycle course, making it one of the more affordable medications in reproductive medicine.

Compounded clomiphene does exist. Specialty compounding pharmacies can prepare it, typically in the same 50 mg tablet form or occasionally as a liquid suspension for patients with swallowing difficulties. The compounded version is not FDA-approved, which carries specific implications for quality oversight that you should understand before choosing it over the generic.

The framework below walks through who actually benefits from compounding, who is better served by the generic or insurance route, and what questions to ask your clinician at each life stage.

What Clomiphene Citrate Actually Does (and Why Dosing Matters for Women)

Clomiphene is a selective estrogen receptor modulator, or SERM. It works by binding to estrogen receptors in the hypothalamus, blocking estrogen's normal negative feedback signal. Your brain then releases more follicle-stimulating hormone (FSH) and luteinizing hormone (LH), prompting your ovaries to develop and release an egg.

Why female physiology changes everything here

The dose-response relationship in women is meaningfully different from what older, male-centered clinical research might suggest. ASRM practice guidelines on ovulation induction recommend starting at 50 mg per day for 5 days (cycle days 3 through 7, or days 5 through 9), with dose escalation to 100 mg only if there is no ovulatory response at 50 mg. Going straight to 150 mg without a proper step-up is common in informal online advice and is not supported by evidence for most women.

Your ovarian reserve matters too. Women with diminished ovarian reserve, typically those in their late 30s or those with a low anti-Müllerian hormone (AMH) level, respond differently to clomiphene than women with normal reserve. Clomiphene may actually be less effective for this group, and injectable gonadotropins or other protocols may be more appropriate, regardless of what the drug costs.

Hormonal status across life stages

• Reproductive years with regular cycles. If you ovulate on your own, adding clomiphene is generally not beneficial and increases the risk of twins or higher-order multiples.
• PCOS. Clomiphene is a first-line agent for ovulation induction in women with PCOS, as established in the ASRM/ESHRE PCOS guideline. Approximately 70 to 85 percent of women with PCOS will ovulate in response to clomiphene, though live birth rates are lower than that figure suggests because not every ovulatory cycle results in a pregnancy.
• Perimenopause and menopause. Clomiphene is not indicated and is not effective in women who have lost the ovarian reserve needed to respond to FSH stimulation. If you are in perimenopause and having irregular cycles, the conversation with your clinician should be about gonadotropins, egg donation, or other approaches, not clomiphene.
• Postpartum. Breastfeeding suppresses ovulation through elevated prolactin. Clomiphene is not appropriate while breastfeeding (see the lactation section below).

The Generic vs. Compounded Decision Tree

Generic clomiphene citrate is manufactured under FDA oversight, meaning each tablet contains the labeled dose of active ingredient, tested for potency and purity. A compounded preparation does not go through that same pre-market review. The FDA has specific guidance on compounded drug quality that describes the standards compounding pharmacies are expected to meet, but enforcement is less rigorous than for commercially manufactured generics.

When compounding genuinely makes sense

• You cannot swallow tablets and need a liquid formulation.
• You have a documented allergy to an excipient (filler) in the commercial tablet, confirmed by allergy testing.
• Your clinic or reproductive endocrinologist uses a compounded protocol that includes clomiphene alongside other agents in a single preparation.

When compounding adds risk without benefit

• You are seeking compounded clomiphene because you believe it will be cheaper. At roughly $30 for a cycle, the generic is already at the floor. A compounding pharmacy's preparation and dispensing fee typically exceeds that price.
• You found an online pharmacy offering "compounded Clomid" without requiring a valid prescription. This is a red flag. Clomiphene is a prescription-only medication in the United States, and any source that sells it without a prescription from a licensed prescriber is operating outside the law.
• You want a higher dose than your prescriber recommended. Compounding pharmacies should not and typically will not prepare a dose that exceeds what is clinically defensible.

How to Get Clomiphene Cheap: The Real-World Access Toolkit

Cost barriers are real, even at $30. If you are paying out of pocket for monitoring ultrasounds, lab work, and potentially multiple cycles, the drug cost compounds quickly. Here are the concrete options.

Generic at major pharmacy chains

GoodRx, Cost Plus Drugs (Mark Cuban's pharmacy), and similar discount programs can bring the cost of generic clomiphene below $20 at some pharmacies. Prices shift frequently; verify current pricing directly before assuming any figure here is current.

Cost Plus Drugs lists clomiphene citrate 50 mg (30 tablets) at their published price, which has historically been well under $20. That price may change; check before your prescription is sent.

Insurance coverage for clomiphene

Coverage depends on your plan and your state. As of 2026, 19 states have passed fertility insurance mandates of some kind, though not all mandate ovulation induction drug coverage specifically. The diagnostic code your prescriber uses matters. A diagnosis of N97.0 (female infertility associated with anovulation) or E28.2 (polycystic ovarian syndrome) may trigger coverage where a more general code would not.

Steps to take:

1. Call the member services number on your insurance card before your appointment.
2. Ask specifically: "Is clomiphene citrate covered under my pharmacy benefit or medical benefit, and what diagnosis codes are required?"
3. Ask your prescriber to include the most specific diagnosis code possible on the prescription.

Clinic-dispensed samples and financial assistance

Some reproductive endocrinology clinics keep samples of generic clomiphene for patients who cannot afford even the cash price. Ask directly. There is no universal manufacturer coupon program for generic clomiphene because it is produced by multiple manufacturers with no single brand-name owner, but individual manufacturers occasionally offer programs. Your pharmacist can tell you whether the specific generic they stock has an associated savings card.

Patient assistance programs and nonprofit resources

• RESOLVE: The National Infertility Association maintains a resource page on fertility financial assistance, including grants and pharmacy discount programs.
• Baby Quest Foundation and The Tinina Q. Cade Foundation offer grants that can cover drug costs as part of broader fertility treatment funding.

These programs change. Verify current availability directly with each organization.

Pregnancy and Lactation Safety (Required Reading Before You Start)

This section is not optional context. It directly affects whether clomiphene is right for you right now.

Pregnancy: FDA Category X

Clomiphene citrate is FDA Pregnancy Category X. This means there is evidence of fetal risk and the risks clearly outweigh any potential benefit during pregnancy. Animal studies showed fetal abnormalities; human data, while limited, does not contradict that signal.

What this means in practice: You take clomiphene to become pregnant, not while pregnant. The protocol requires a negative pregnancy test before each cycle. If you become pregnant during a cycle and inadvertently continue clomiphene, stop the medication immediately and contact your prescriber. Continued use does not automatically mean fetal harm, but the drug should not continue.

Any source, online or otherwise, that sells or recommends clomiphene for use during a confirmed pregnancy is providing dangerous, incorrect information.

Contraception requirement

This may seem counterintuitive for a drug used to induce ovulation, but the Category X designation means that women who are prescribed clomiphene for off-label reasons (such as experimental use in perimenopausal hormone management, which is not evidence-based) and who are not actively trying to conceive should use reliable contraception. If you are using clomiphene specifically to conceive, the "contraception" in practice is the structured monitoring protocol, confirming ovulation and pregnancy status each cycle.

Lactation

Clomiphene is not recommended during breastfeeding. The concern is twofold: clomiphene may suppress prolactin and reduce milk supply, and the potential for transfer to the infant has not been adequately studied. If you are postpartum and trying to conceive again while still breastfeeding, discuss timing with your clinician. Most reproductive endocrinologists prefer to wait until breastfeeding has concluded or is significantly reduced before initiating clomiphene.

Conditions Where Clomiphene Is (and Isn't) the Right Choice

PCOS

PCOS is the most common indication for clomiphene in women of reproductive age, affecting approximately 8 to 13 percent of women globally. Clomiphene is effective for ovulation induction in PCOS, though the PPCOS II trial (New England Journal of Medicine, 2012) found that letrozole produced higher live birth rates than clomiphene in women with PCOS, with a live birth rate of 27.5 percent for letrozole versus 19.1 percent for clomiphene. That trial enrolled 750 women and ran for up to 5 treatment cycles. Letrozole is now often preferred as first-line in PCOS, though clomiphene remains widely used and is appropriate when letrozole is not available or not covered.

Unexplained infertility

Clomiphene alone for unexplained infertility in women who already ovulate has not shown consistent benefit in randomized trials. The FASTT trial (New England Journal of Medicine, 2009) found that moving directly from clomiphene to injectable gonadotropins with intrauterine insemination, skipping clomiphene plus IUI, reduced time to pregnancy without increasing multiple birth rates. This does not mean clomiphene is wrong for unexplained infertility, but it should be part of a structured conversation with your provider rather than a default.

Hypogonadotropic hypogonadism

Women with very low FSH and LH due to hypothalamic causes (low body weight, excessive exercise, stress) typically do not respond well to clomiphene because the hypothalamic-pituitary axis needs to be functional for the drug to work. Injectable gonadotropins are the usual alternative.

Diminished ovarian reserve

If your AMH is low and your antral follicle count is low for your age, clomiphene is unlikely to be effective. This applies especially to women over 37. The ACOG Practice Bulletin on Female Age-Related Fertility Decline notes that ovarian response to stimulation decreases significantly with age, and clomiphene in particular may perform poorly in this group.

Who This Is Right For, and Who Should Think Twice

This medication may fit you if you:

• Have confirmed anovulation or oligo-ovulation (irregular cycles, no LH surge detected)
• Have a diagnosis of PCOS and are actively trying to conceive
• Have normal ovarian reserve for your age
• Are in your reproductive years (roughly 18 to 37, though age alone is not the cutoff; ovarian reserve testing matters more)
• Have a prescribing clinician who will monitor you with cycle-day ultrasound and bloodwork

Consider a different approach if you:

• Ovulate regularly on your own; clomiphene increases multiples risk without clear conception benefit in ovulatory women
• Are perimenopausal or postmenopausal; clomiphene will not restore ovulation
• Are currently pregnant or breastfeeding
• Have already completed 6 ovulatory cycles on clomiphene without conception; ASRM guidelines do not recommend continuing beyond that point without re-evaluation
• Have a history of ovarian cysts, liver disease, or abnormal uterine bleeding that has not been evaluated

Monitoring: What Responsible Use Looks Like

Taking clomiphene without monitoring is not recommended. Before starting, you need:

• A baseline pelvic ultrasound to rule out ovarian cysts (if a cyst is present, starting clomiphene can make it worse)
• Cycle day 2 to 3 FSH, LH, estradiol, and AMH to assess ovarian reserve
• A negative pregnancy test

During a cycle, a midcycle ultrasound around day 12 to 14 confirms whether follicles are developing and whether ovulation is likely. Some clinicians also use an LH urine surge test or a day-21 progesterone blood draw to confirm ovulation occurred.

This monitoring adds to your total cost, which is worth knowing before you decide that $30 for the drug is the whole picture.

The Evidence Gap: What We Don't Know About Clomiphene in Women

Women have been historically underrepresented in pharmacokinetic trials, and clomiphene is no exception. Most PK data comes from studies conducted in the 1970s and 1980s, with small sample sizes and limited diversity. What we know:

• Clomiphene has a long half-life (approximately 5 to 7 days for the active isomers) and can accumulate with repeated cycles, which partially explains the cervical mucus thinning and endometrial effects seen in some women after multiple cycles.
• The ratio of the two isomers (zuclomiphene and enclomiphene) matters clinically. Enclomiphene is the more potent ovulation inducer; zuclomiphene persists longer and may account for more of the side effects. Compounded preparations may not standardize this ratio the way commercial generics do, though data directly comparing compounded to generic in women is essentially absent.
• Long-term ovarian cancer risk was a concern in early observational studies, but a 2023 systematic review in BJOG did not find a statistically significant increased risk attributable to clomiphene use beyond the background risk associated with infertility itself.

These are extrapolated points, not conclusions from large randomized trials in representative populations of women. Your prescriber should know your specific history before applying population-level data to your case.

Practical Next Steps by Life Stage

Trying to conceive, reproductive years: Ask your OB-GYN or reproductive endocrinologist for baseline ovarian reserve testing before starting. Use the GoodRx or Cost Plus Drugs price to compare against your insurance copay. Bring your insurance card information and ask the prescriber's office to check prior authorization requirements before the prescription is sent.

PCOS, any reproductive-age stage: Ask specifically whether letrozole has been considered first, given the PPCOS II trial data. If insurance covers one and not the other, cost may reasonably influence the choice, but that is a conversation to have with clinical support, not a decision to make based on internet pricing alone.

Perimenopausal: Clomiphene is not the right tool. Ask your clinician about ASRM guidance on fertility in women over 40 and what evaluation you need before deciding on a path.

Postpartum, wanting to conceive again: Wait until you have had at least one or two natural cycles return after weaning, or discuss timing with your OB or reproductive endocrinologist. Clomiphene use before cycles have resumed is unlikely to be effective and is not appropriate while breastfeeding.

Your prescriber should confirm all pricing and program availability at the time of your appointment. Programs listed here change frequently, and a number that was accurate when this was written may not be current when you read it.